Cara begins Phase 2 trial of pruritus treatment in dermatitis patients
Category: #health  By Mateen Dalal  Date: 2019-07-11
  • share
  • Twitter
  • Facebook
  • LinkedIn

Cara begins Phase 2 trial of pruritus treatment in dermatitis patients

The study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus

Biopharmaceutical firm Cara Therapeutics Inc. has reportedly announced the initiation of their Phase 2 trial of Oral KORSUVATM for pruritus treatment in patients diagnosed with atopic dermatitis (AD). Evidently, AD is one of the leading chronic inflammatory diseases with occurrence rates of close to 25% in children and approximately 5% in adults.

Dr. Derek Chalmers, Cara President and CEO, was quoted saying that pruritus is a key defining feature of AD that considerably affects patients’ quality of life. He added that the company looks forward to initiating the Phase 2 trial to evaluate Oral KORSUVA as a potential oral treatment option for the treatment of pruritus.

Apparently, the Phase 2 randomized, placebo-controlled, double-blind study is formulated to evaluate the safety and efficacy of Oral KORSUVA for moderate to severe pruritus in 240 adult patients having AD. The subjects will be randomly administered with three tablet strengths of the drug, 0.25mg, 0.5mg and 1mg, taken twice daily vs. placebo for 12 weeks followed by a 4-week active extended phase.

Sources familiar with the study reported that the primary efficacy endpoint will be the change from reference point in the weekly mean of the 24hour I-NRS score at week 12. Whereas the secondary endpoints includes change from starting point in itch-related scores at the end of the 12th week as evaluated by Skindex 5-D and 10 itch scales, as well as the number of patients reaching baseline of more than or equal to 4 points with respect to the weekly mean of the daily 24 hour I-NRS score at week 12.

It has come to the fore that the point occurrence of chronic pruritus in AD ranges between 87% and 100%. Seemingly, both psychosocial well-being and quality of life are known to correlate with the severity of the itch.

Source credit: http://ir.caratherapeutics.com/news-releases/news-release-details/cara-therapeutics-announces-initiation-phase-2-trial-oral-0

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
Air France-KLM & JAL make bids to purchase stake in Malaysia Airlines
By Mateen Dalal

Air France–KLM S.A., one of the leading global air transport players, has reportedly made a proposal to invest in Malaysia Airlines and gain around 49 percent stake. Japan Airlines (JAL) is also looking to acquire a 25 percent stake in Mal...

Accenture opens innovation center in South Beach Road office
Accenture opens innovation center in South Beach Road office
By Mateen Dalal

Accenture, an Irish multinational professional services company, has recently opened a global innovation center within the Accenture’s office at South Beach Road, which is supported by EDB (Economic Development Board) in Singapore. It will pro...

Verrica unveils positive data from VP-102 study in molluscum treatment
Verrica unveils positive data from VP-102 study in molluscum treatment
By Mateen Dalal

Findings from the study are being produced at the 17th Annual Winter Clinical Dermatology Conference in Kohala Coast The data indicated a considerable increase in the percentage of patients with lesion clearance in VP-102 group Verrica Pharmaceu...